VALIDATE-BSI 2019 Conference:
Vaccine Development for Neglected Intracellular Pathogens

VENUE: The Grand Hall & Winter Gardens at The Drum at Wembley, London
https://www.thedrumatwembley.com/

Wednesday 2 October 2019 (afternoon and evening)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1200</td>
<td>Registration and buffet lunch for all delegates</td>
</tr>
<tr>
<td>1300</td>
<td><strong>Prof Helen McShane</strong>&lt;br&gt;VALIDATE Director, University of Oxford, UK&lt;br&gt;Welcome to conference &amp; introduction to VALIDATE</td>
</tr>
<tr>
<td>1310</td>
<td><strong>Dr Doug Brown</strong>&lt;br&gt;Chief Executive, British Society for Immunology, UK&lt;br&gt;BSI Welcome address</td>
</tr>
<tr>
<td>1320</td>
<td><strong>Session 1: Tissue-specific immunity, host-pathogen interactions,</strong>&lt;br&gt;macrophages and the microenvironment (Chair: <strong>Prof Andrea Cooper</strong>, University of Leicester, UK)</td>
</tr>
<tr>
<td>1320</td>
<td><strong>Keynote speaker: Prof Clare Lloyd</strong>&lt;br&gt;Imperial College London, UK&lt;br&gt;Local and environmental cues dictate the nature of the pulmonary immune response</td>
</tr>
<tr>
<td>1400</td>
<td><strong>Dr Barbara Kronsteiner-Dobramysl</strong>&lt;br&gt;University of Oxford, UK&lt;br&gt;Diabetes alters cellular metabolism of T cells: implications for vaccine development</td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>1420</td>
<td>Dr Chidchamai Kewcharoenwong</td>
</tr>
<tr>
<td>1440</td>
<td>Dr Isadora Lima</td>
</tr>
<tr>
<td>1500</td>
<td></td>
</tr>
<tr>
<td>1530</td>
<td><strong>Keynote speaker:</strong> Prof Tracy Hussell</td>
</tr>
<tr>
<td>1550</td>
<td>Dr Lisa Stockdale</td>
</tr>
<tr>
<td>1610</td>
<td></td>
</tr>
<tr>
<td>1630</td>
<td>Asst Prof Kiran Afshan</td>
</tr>
<tr>
<td>1634</td>
<td>Dr Anthony Afum-Adjei Awuah</td>
</tr>
<tr>
<td>1638</td>
<td>Dr Federico Carlos Blanco</td>
</tr>
<tr>
<td>1642</td>
<td>Assoc Prof Mary Burtnick</td>
</tr>
<tr>
<td>1646</td>
<td>Dr Panjaporn Chaichana</td>
</tr>
<tr>
<td>1650</td>
<td>Assoc Prof Narisara Chantratita</td>
</tr>
</tbody>
</table>
| 1654 | **Asst Prof Ganjana Lertmemongkolcha**  
Khon Kaen University, Thailand  
Metformin-induced suppression of IFN-α expression via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in diabetes mellitus |
| 1658 | **Dr Rachel Okojie**  
University of Benin, Nigeria  
Comparative study of the immunological and haematological parameters among tuberculosis naive and treated patients in Central Hospital, Benin City, Nigeria |
| 1702 | **Dr Olayinka Osuolale**  
Elizade University, Nigeria  
Leishmaniasis in patients attending a medical health center in the rural community of Ilara-Mokin, Ondo State, Nigeria |
| 1706 | **Asst Prof Vijay Kumar Prajapati**  
Central University of Rajasthan, India  
Evaluation of immunogenicity of the engineered multi-epitope subunit vaccine against visceral leishmaniasis infection |
| 1710 | **Dr Lok Bahadur Shrestha**  
BP Koirala Institute of Health Sciences, Nepal  
Emerging Clinical Microbiologist looking for research opportunity in TB Vaccinology |
| 1714 | **Dr Suwarti**  
Eijkman Oxford Clinical Research Unit (EOCRU), Indonesia  
Intranasal boosting regimen of Human Parainfluenza Virus Type 2-Ag85B vaccines induces superior CD4 immune response against *Mycobacterium tuberculosis* |
| 1718 | **Dr Julen Tomás Cortázar**  
University College Dublin, Ireland  
Elucidating the mechanisms of protection of the *Burkholderia pseudomallei* antigen, BpOmpW |
| 1722 | **Chathika Weersuriya**  
LSHTM, UK  
Mathematical modelling of the epidemiological impact, cost-effectiveness and budget impact of novel tuberculosis vaccines on multi-drug resistant tuberculosis |
| 1730 | Group photograph |
| 1900+ | Conference Dinner |
### Thursday 3 October 2019 (full day)

<table>
<thead>
<tr>
<th>Start</th>
<th>End</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830</td>
<td></td>
<td>Coffee/tea</td>
</tr>
<tr>
<td>0900</td>
<td></td>
<td><strong>Session 2: Biomarkers (including omics &amp; Big Data)</strong> (Chair: Prof Helen Fletcher, LSHTM, UK)</td>
</tr>
</tbody>
</table>
| 0900   |       | **Keynote speaker:** [Dr January Weiner](#) Berlin Institute of Health, Germany, Germany  
Biomarkers in tuberculosis and individual variability of the host |
| 0940   |       | [Dr Fatoumatta Darboe](#) MRC The Gambia  
Predicting and diagnosing TB disease in HIV-infected persons |
| 1000   |       | [Dr Eduardo Milton Ramos Sanchez](#) USP, Brazil  
Altered expression of microRNAs in infections with cutaneous and visceral strains of Leishmania |
| 1020   |       | **Tea/coffee break**                                                                                                                  |
| 1050   |       | **Keynote speaker:** [Prof Stephen Gordon](#) University College Dublin, Ireland  
One Health route to exploring virulence in the *Mycobacterium tuberculosis* complex |
| 1130   |       | [Hannah Painter](#) LSHTM, UK  
Development of an ex vivo mycobacterial inhibition assay using murine lung cells for tuberculosis vaccine testing |
| 1150   |       | [Asst Prof Tufária Mussa](#) Eduardo Mondlane University, Mozambique  
The fusion protein Ag85B-HBHA (FP1) elicits IFN-γ, IL-2 and TNF-α in conventional T cells of tuberculosis contacts with latent infection over time |
| 1210   | 1310  | **Lunch**                                                                                                                              |
| 1310   |       | **Session 3: Latest vaccine developments** (Chair: [Prof Helen McShane](#), University of Oxford, UK)                                   |
| 1310   |       | **Keynote speaker:** [Assoc Prof Paul Brett](#) University of Nevada, Reno, USA  
Development of multivalent subunit vaccines for immunization against melioidosis |
| 1350   |       | [Dr Sophie Rhodes](#) LSHTM, UK  
Dose finding for new vaccines: the role for immunostimulation/immunodynamic modelling |
1410  
**Dr Deepa Paliwal**  
University of Reading, UK  
Progress in reverse vaccinology approach for bovine TB

1430 - 1500  
**Tea/coffee break**

1500  
*Keynote speaker: Prof Mark Hatherill*  
University of Cape Town, South Africa  
Major advances and next steps for tuberculosis vaccine development

1540  
**Dr Justice Boakye-Appiah**  
SGUL, UK  
Mycolactone based vaccine against Buruli ulcer disease

1600  
**Asst Prof Rebecca Harris**  
LSHTM, UK  
Potential impact of new tuberculosis vaccines in China, South Africa and India and implications for vaccine development

1620  
**Prof Helen McShane**  
VALIDATE Director, University of Oxford, UK  
Wrap up and conference close

1630  
**End of conference**

**Conference Registration charges:**

1) VALIDATE and/or BSI members:
   a) Non-industry members:
      i) LMIC members  
         Free  
      ii) Non-LMIC members  
         £50  
   b) Industry members  
      £75  

2) Non-members of VALIDATE or BSI  
   £100

To register, visit: [https://www.validate-network.org/annual-meeting](https://www.validate-network.org/annual-meeting)